Archive for Stock Market News

News US may lower China tariffs buoys markets

By IFCMarkets

Dollar strengthening stalls

US stock market rose third straight session on Thursday on reports Washington was considering easing tariffs on Chinese imports to facilitate trade talks. The S&P 500 rose 0.8% to 2635.96. The Dow Jones industrial average gained 0.7% to 24370.10. Nasdaq composite index added 0.7% to 7084.46. The dollar strengthening halted despite a report the Federal Reserve Bank of Philadelphia’s manufacturing index rebounded in January: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, inched lower to 96.06 but is higher currently. Stock index futures indicate higher openings today.

FTSE 100 leads European Index losses

European stocks ended marginally higher on Thursday despite disappointing bank earnings reports. The EUR/USD continued its slide while GBP/USD extended gains with both reversing directions currently. The Stoxx Europe 600 index gained 0.04%. Germany’s DAX 30 however slipped 0.1% to 10918.62. France’s CAC 40 slid 0.3% and UK’s FTSE 100 fared the worst ending 0.4% lower at 6834.92 as Prime Minister Theresa May starts cross-party discussions to arrive at an acceptable compromise to the rejected Brexit deal.

Chinese stocks lead Asian indices gains

Asian stock indices resumed advancing today on US-China trade talk progress hopes. Nikkei rose 1.3% to 20666.07 with yen slide against the dollar intact. Chinese indices are higher as Beijing announced China’s top trade official, Vice Premier Liu He, will travel to the US for January 30-31 talks. The Shanghai Composite Index is up 1.4% and Hong Kong’s Hang Seng Index is 1.2% higher. Australia’s All Ordinaries Index extended gains 0.5% despite continued Australian dollar climb against the greenback.

Nikkei rises toward ascending channel   01/18/2019 Market Overview IFC Markets chart

Brent rises

Brent futures prices are advancing today. Prices retreated yesterday: Brent for March settlement closed 0.2% lower to $61.18 a barrel on Thursday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Phase 2 Study Begins for German Biopharma’s Cancer Drug Candidate

By The Life Science Report

Source: Streetwise Reports   01/16/2019

A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated.

In a Jan. 14 research note, analyst Sam Slutsky reported the Phase 2 EMERGE clinical trial evaluating 4SC AG’s (VSC:FSE Prime Standard) domatinostat with Bavencio (avelumab) in patients with microsatellite-stable esophagogastric cancer and colorectal cancer.

Enrollment of patients, which will total up to 70, started at the first study locations. The goal of the trial is to show safety of the combination therapies and generate proof-of-concept data. Initial results could be released in H2/19.

“This event marks continuing progress in the development of domatinostat,” Slutsky pointed out. This selective histone deacetylase inhibitor is now being evaluated in combination with Keytruda in SENSITIVE, an ongoing Phase 1b/2 trial in melanoma that is refractory/unresponsive to anti-PD-1. A third dose cohort in SENSITIVE got underway recently, after the second dose group showed a positive safety profile and the Safety Review Committee, in December 2018, recommended proceeding. Topline results from SENSITIVE are expected in mid-2019.

Should data from EMERGE and SENSITIVE be positive, 4SC plans to pursue a trial evaluating the combination of domatinostat and a checkpoint inhibitor in advanced Merkel cell carcinoma (MCC), wrote Slutsky. Preclinical MCC data are expected in H1/19.

4SC’s stock is currently trading at around €3.10 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from LifeSci Capital, 4SC AG, Company Update, January 14, 2019

Analyst Certification: The research analyst denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies), with respect to each security or subject company that the research analyst covers in this research, that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or subject companies, and (2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report.

DISCLOSURES
Neither the research analyst(s), a member of the research analyst’s household, nor any individual directly involved in the preparation of this report has a financial interest in the securities of the subject company.
LSC (or an affiliate) has received compensation from 4SC AG for producing this research report. LSC is paid a monthly payment of $1,000 from the Affiliate for preparing and distributing research pertaining to each subject company under contract with the Affiliate. The subject company of this report is covered by this arrangement between LSC and the Affiliate, and LSC has therefore indirectly received compensation from the subject company for publishing this report. No explicit or implicit promises of favorable research coverage have been made to the subject company by LSC or the Affiliate. Neither LSC nor the Affiliate has promised any specific research content as an inducement for the receipt of business or compensation.
LSC (or an affiliate) has also provided non-investment banking securities-related services, non-securities services, and other products or services other than investment banking services to 4SC AG and received compensation for such services within the past 12 months.
Neither LSC nor any of its affiliates beneficially own 1% or more of any class of common equity securities of the subject company.
This research contains the views, opinions and recommendations of LifeSci Capital, LLC (“LSC”) research analysts.
Additionally, LSC expects to receive or intends to seek compensation for investment banking services from the subject company/ companies in the next three months.
LSC does not make a market in the securities of the subject company/companies.

Please visit http://www.lifescicapital.com/equity-research/ for disclosures related to each company that is a subject of this report.

( Companies Mentioned: VSC: FSE Prime Standard,
)

NIKKEI Analysis: Increasing bank lending bullish for NIKKEI

By IFCMarkets

Increasing bank lending bullish for NIKKEI

Japanese bank lending increased in December. Will the NIKKEI continue rising?

Recent Japanese economic data were positive: while the growth in core machinery orders slowed in November from 4.5% over year in October, it still amounted to 0.8% instead of expected 0.2%. At the same time bank lending increased more than expected: from 2.1% over year in November to 2.4% in December, above expectations of a 2.2% increase. And as Chinese delegation plans to visit Washington in the end of January to continue US-China trade talks and Beijing pledging to provide fiscal and monetary stimulus for its economy to boost the slowing growth, the outlook for global economic growth is being upgraded, adding to investors optimism. Improving business optimism is bullish for NIKKEI.

NIKKEI tests Fibonacci 23.6 level 01/17/2019 Technical Analysis IFC Markets chart

On the daily timeframe the Nikkei: D1 is rising after hitting 19-mont low in the end of December. The price is above the 23.6 Fibonacci level, this is bullish.

  • The Parabolic indicator gives a buy signal.
  • The Donchian channel indicates uptrend: it is narrowing up.
  • The MACD indicator gives a bullish signal: it is below the signal line and the gap is narrowing.
  • The Stochastic oscillator is rising but has not reached the overbought zone yet.

We believe the bullish momentum will continue after the price closes above the upper boundary of Donchian channel at 20574.5. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the fractal low at 20033.0. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (20033.0) without reaching the order (20574.5), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Technical Analysis Summary

Position Buy
Buy stop Above 20574.5
Stop loss Below 20033.0

Market Analysis provided by IFCMarkets

Bank rally leads US stocks advance

By IFCMarkets

Nasdaq tests 50-day moving average

US stock market advanced second straight session on Wednesday led by financial shares after upbeat bank earnings reports. The S&P 500 gained 0.2% to 2616.10. The Dow Jones industrial average advanced 0.6% to 24207.16. Nasdaq composite index added 0.2% to 7034.69, closing above 50-day moving average. The dollar strengthening continued as home builder confidence rebounded from a three-year low in January: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, rose 0.1% to 96.065 and is higher currently. Stock index futures point to lower openings today.

Nasdaq tests MA(50)   01/17/2019 Market Overview IFC Markets chart

Brexit deal rejected by UK parliament

European stocks extended gains on Wednesday led by banking shares. EUR/USD continued falling while GBP/USD turned higher ahead of Brexitr deal vote with both pairs lower currently. The Stoxx Europe 600 closed 0.5% higher. Germany’s DAX 30 rose 0.4% to 10931.24, France’s CAC 40 gained 0.5% while UK’s FTSE 100 lost 0.5% to 6862.68. Prime minister May’s brexit proposal was voted down in Parliament and the UK government narrowly survived a no-confidence vote.

Australian stocks rise while other Asian indices fall

Asian stock indices are mixed today. Nikkei slipped 0.2% to 20402.27 as yen climb against the dollar resumed. China’s stocks are falling after reports US prosecutors were investigating China’s Huawei Technologies for allegedly stealing trade secrets from American companies: the Shanghai Composite Index is down 0.4% while Hong Kong’s Hang Seng Index is 0.5% lower. Australia’s All Ordinaries Index extended gains 0.3% as the Australian dollar slide against the greenback endured.

Brent down despite US crude stocks dip

Brent futures prices are lower today. Prices rallied yesterday buoyed by the Energy Information Administration reports US crude stockpile fell 2.7 million barrels last week though domestic output rose. March Brent crude rallied 1.1% to $61.32 a barrel on Wednesday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

US Indexes Reaches Fibonacci Target Zone – Where to Next?

By TheTechnicalTraders.com

Near December 21, 2018, our research team began a series of posts indicating the US Major Indexes should be set up for the “Ultimate Bottom” low that we suggested would take place after the US Elections (November 2018) and which would launch an upside price rally.  Today, we are writing to announce that the first leg of this upside move appears to be nearly completed.

It is critical to mention here that as of only a day go the short-term market trend from a technical standpoint has turned up. So, getting long before this point would be trying to catch a bottom which is tough and risky to do. The good news is that we are expecting a second leg higher after we get some rotation to the downside.

Using our Adaptive Fibonacci Price Modeling system, we can see that the current prices of the ES and NQ are very near to the immediate Fibonacci Price Target Zone.  You will see from the following charts that both the ES and NQ are already within this zone and/or very near to what we believe will be immediate resistance.  This means we should expect a bit of price rotation near these levels before another upside leg takes place driving prices higher.

This first Daily ES chart shows the Fibonacci Target Zone clearly in Green.  You can see how price has rallied up to near this level and may even rally a bit further before rotating downward a bit.  Remember, price rotation in a trend is very healthy for normal markets.  When price moves extensively in one direction or another is somewhat unhealthy and dangerous.  When price moves up or down in rotating waves or price cycles, this is a very healthy means for the price to establish support/resistance and to wash out groups of traders that may be biased in the markets.

 

This Daily NQ chart shows a very similar, although more narrow, Fibonacci Target Zone.  The result is virtually the same as the ES chart.  Price should attempt to establish some resistance within this zone and the potential for a downside price rotation increases near this level.  We are expecting a downward price move, possibly toward the BLUE Fibonacci downside target square level, before the price rally resumes to drive prices above recent highs and into the next leg higher.

 

If you have followed our analysis, on September 17, 2018, we predicted 4~5 months into the future what would likely happen.  Our call for an “Ultimate Low” price reversal after the Nov 2018 elections appears to be setting up perfectly.  Although we did not predict this extreme low price level in that research post, the overall expectations we had in September were nearly perfect.

If the remainder of our analysis continues to play out as accurately, we should be setting up for a very big move to the upside over the next couple of months.  It will likely be paired with decent earnings data from the US, moderately strong economic data and the resulting economic improvements of a China Trade Deal and the resolution to the US Government Shutdown.  The issues in Europe are set to reach a peak somewhere near March or April 2018.  We expect the US markets to be trading several percents higher by that time.

Pay attention to these markets moves.  2019 is poised to be a very exciting and profitable year for skilled traders and wise investors.  Visit TheTechnicalTraders.com to get our daily and weekly analysis forecast complete with long term investing swing trading, and index day trade signals.

53 years experience in researching and trading makes analyzing the complex and ever-changing financial markets a natural process. We have a simple and highly effective way to provide our customers with the most convenient, accurate, and timely market forecasts available today. Our index, stock and ETF trading alerts are readily available through our exclusive membership service via email and SMS text. Our newsletter, Technical Trading Mastery book, and 3 Hour Trading Video Course are designed for both traders and investors. Also, some of our strategies have been fully automated for the ultimate trading experience.

Chris Vermeulen

 

 

Technology rally leads US stocks gains

By IFCMarkets

Dollar strengthens while wholesale inflation keeps pace

US stock market resumed advancing on Tuesday as technology shares rallied after Netflix announced it would raise US prices by 13% to 18%. The S&P 500 rose 1.1% to 2610.30. Dow Jones gained 0.7% to 24065.59. The Nasdaq climbed 1.7% to 7023.83. The dollar strengthened as data showed wholesale inflation – prices paid by businesses for inputs, remained unchanged at 2.5% over year in December. The live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, rose 0.4% to 95.96 and is higher currently. Stock index futures point to higher openings today.

FTSE 100 outperforms European indexes as UK rejects Brexit plan

European stocks advanced on Tuesday erasing most of previous session losses. Both GBP/USD and EUR/USD turned lower but are higher currently as Prime Minister Theresa May’s plan to leave the European Union by a March 29 deadline was rejected by the UK parliament. The Stoxx Europe 600 gained 0.4%. The German DAX 30 added 0.3% to 10891.79, France’s CAC 40 rose 0.5% and UK’s FTSE 100 rallied 0.6% to 6895.02.

GB100 tests MA(50)   01/16/2019 Market Overview IFC Markets chart

Nikkei falls while Asian indices gain

Asian stock indices are mixed today. Nikkei fell 0.6% to 20442.75 as yen turned higher against the dollar. Chinese stocks are higher: the Shanghai Composite Index is up 0.1%, and Hong Kong’s Hang Seng index is 0.2% higher. Australia’s All Ordinaries Index rose 0.4% despite the Australian dollar continuing climb against the greenback.

Brent up ahead of US inventory report

Brent futures prices are extending gains today. Prices ended higher yesterday on hopes China’s economy will get the boost pledged by Beijing. The American Petroleum Institute late Tuesday report indicated US crude inventories dropped by 0.56 million barrels last week while gasoline inventories rose. March Brent rallied 2.8% to $60.64 a barrel on Tuesday. Today at 16:30 CET the Energy Information Administration will release US Crude Oil Inventories.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Biotech’s Flu Vaccine Shows ‘Superiority to Market Leader’ in Data

By The Life Science Report

Source: Streetwise Reports   01/11/2019

Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report.

In a Jan. 10 research note, analyst Michael Higgins with Ladenburg Thalmann reported that Novavax Inc. (NVAX:NASDAQ) just released updated Phase 2 data that show NanoFlu’s “superiority to the market leader” Fluzone HD in several H3N2 strains that cause the most deaths.

In the trial, Novavax’s eggless flu vaccine was assessed against two comparators, including Fluzone HD, in adults aged 65 and older. Newly released results were from day 28 of the study.

Higgins highlighted the significant advantages of NanoFlu. One, a finding that was revealed in the newly released data, is its efficacy against “drifted strains” that can be deadly, as well as against homologous strains.

“Efficacy against drifted strains is likely the most difficult to get and is the best indication of how a vaccine will handle the annual variability that stumps so many flu vaccines,” Higgins added. “The mismatching between the recommended strains and the actual flu strains produces the sharp year-to-year differences in flu deaths.”

Another benefit of NanoFlu is it eliminates the potential for “virus egg adaptations” through its egg-free manufacturing of the product, the analyst stated.

Higgins concluded that “based on Phase 2 results, we believe that NanoFlu could become the new standard of care for older adults.”

Next for NanoFlu are further data releases from the Phase 2 study. Also, Novavax will meet with the FDA, likely in April, to discuss the Phase 2 study results, a Phase 3 trial design and the potential for faster approval of the vaccine. An accelerated pathway would mean the Phase 3 study could launch in Q4/19 and end in early Q1/20. “We believe such a path is possible,” indicated Higgins.

Ladenburg Thalmann has a Buy rating and a $3.50 per share price target on Novavax, whose stock is currently trading at around $2.17 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from Ladenburg Thalmann, Novavax, Inc., January 10, 2019

ANALYST CERTIFICATION: I, Michael Higgins, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm’s total revenues, a portion of which is generated by investment banking activities.

COMPANY SPECIFIC DISCLOSURES
Ladenburg Thalmann & Co. Inc. makes a market in Novavax, Inc.
Ladenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Novavax, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc. intends to seek compensation for investment banking and/or advisory services from Novavax, Inc. within the next 3 months.
Ladenburg Thalmann & Co. Inc received compensation for investment banking services from Novavax, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc had an investment banking relationship with Novavax, Inc. within the last 12 months.

( Companies Mentioned: NVAX:NASDAQ,
)

Are Global Stock Markets About To Rally 10 Percent?

By TheTechnicalTraders.com

Technical Traders Ltd. is issuing new analysis which indicates the US and global markets may be poised for a dramatic upside price swing over the next couple.  Recent events have driven asset class values to new valuations that may change the dynamics of markets for a few months.  Prior to August/September 2018, many traders were fearful of the expectations of the US Federal Reserve, Global Trade Issues and the US Elections. Combine this with the end of the year liquidity issues and the threat of a US government shutdown over the wall funding and we have almost a perfect storm brewing for uncertainty and fear.

Now, it appears, our custom global market indexes are showing signs that a bottom may have formed over the past few weeks and that the global equities markets may be poised for an upside move in the range of +10% to +20% over the next 2-4 months.

“What changed over the past month?”, you might be asking?  Valuation levels have changed.  The chart below is a Weekly chart of our Custom Smart Cash index.  We use this as a measure of global equity market valuation and to determine if and when pricing levels are changing in terms of total market capitalization.  We can see from early 2018, the global markets peaked and began to move lower.  Even though the US markets pushed higher throughout this time, the total global markets continued to deteriorate.  Now, the valuation levels are near historic channel support and have begun to flip back to the upside (at least in the immediate term).  If this continues as capital re-enters the global capital markets in search of undervalued opportunities, this capital will find quite a few opportunities in beaten up global equities.  Pay attention because this could be the setup of a market bottom with relatively strong upside potential.

 

One item to pay attention to is our Custom China/Asia index.  This chart, below, is a Monthly Custom China/Asia market index.  It may be somewhat hard to understand with all of these Fibonacci Arcs drawn on it, but to us, this is a very clear chart.  These Arcs are an advanced way to look at Fibonacci price support and resistance.  We look for how these arcs relate to price activity and how they converge in past and future price points.  Our belief is that each price move initiates and perpetuates with a certain energy level and frequency.  If we are able to identify this level and frequency, then we may be able to attain greater knowledge of the future price turning points, support, resistance, and other key information.  As you can see, the bottom on this chart occurred right within the Top Arc’s primary frequency levels near 4.5x the base frequency level – or 2x the immediate frequency level.  This is a fairly common level for the price to form tops/bottoms.  2X equals 200% of an immediate price level energy frequency.

We believe China/Asia may experience an upside price swing of nearly +8 to +15% over the next couple of months as the global markets attempt a price recovery.  This means that there may be some opportunity in the Asian markets through April/May 2019.  We urge investors to be cautious of the Summer months of 2019 because we don’t expect this move to last long.

 

This means skilled traders will be able to find and execute a broad range of successful and profitable trading opportunities over the next 2 to 4 months.  Get ready for 2019 to be a very good year for traders and learn how our daily market research, stock, ETF, and futures trading signals can save your time and money. Start executing the best opportunities today with TheTechnicalTraders.com.

Chris Vermeulen

 

All three US main indices snap 5-session streak

By IFCMarkets

Dollar strengthening decelerates on slower inflation

US stock market ended marginally lower on Friday. S&P 500 slipped 0.01% to 2596.23, closing 2.5% higher for the week. Dow Jones industrial average slid 0.02% to 23995.95. The Nasdaq lost 0.2% to 6971.48. The dollar strengthening slowed as data indicated inflation slowed to 1.9% in December from 2.2% in November: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, rose 0.1% to 95.67 but is lower currently. Stock index futures point to lower openings today.

SP500 test descending channel   01/14/2019 Market Overview IFC Markets chart

DAX 30 loss smaller than other European indices

European stocks finished marginally higher on Friday. The EUR/USD continued falling while GBP/USD turned higher on reports of a likely Brexit delay with euro higher currently as Pound slips. The Stoxx Europe 600 Index inched up 0.1%, ending the week 1.7% higher. The DAX 30 lost 0.3% to 10887.46 led by auto-makers shares after reports Ford plans job custs and plant closures in Europe. France’s CAC 40 fell 0.5% and UK’s FTSE 100 slid 0.4% to 6918.18.

Hang Seng leads Asian indices losses

Asian stock indices are lower today as China reported weak trade data. Stock market in Japan is closed for a holiday while yen resumed its climb against the dolla . Chinese stocks are falling as Beijing reported slower exports: the Shanghai Composite Index is down 0.7% and Hong Kong’s Hang Seng Index is 1.6% lower. Australia’s All Ordinaries Index inched 0.02% lower despite the Australian dollar turn lower against the greenback.

Brent rally snaps

Brent futures prices are extending losses today. Prices ended lower on Friday: Brent for March settlement slid 2.0% to close at $60.48 a barrel Friday, rising 6% for the week.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Healthcare Solutions Provider to Acquire Medical Software Firm

By The Life Science Report

Source: Streetwise Reports   01/10/2019

The merger will allow the Canadian company to expand its online technology platform.

Premier Health Group Inc. (PHGI:CSE; PHGRF:OTCQB; 6PH:FSE) announced in a news release it signed a definitive agreement to acquire the outstanding securities of Cloud Practice Inc., a national medical software company.

Cloud’s products include a cloud-based electronic medical records application, a medical billing software program and an online patient portal. The company’s clients encompass medical practices, licensed health care providers, cannabis clinics and registered patients.

In the merging of the two companies, Cloud Practice’s CEO Jordan Visco and team of software developers and salespeople will stay on with the combined entity that will have a base of more than 300,000 patients.

“With this acquisition, we now have a medical software company with national reach, thus enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records system,” Premier CEO Dr. Essam Hamza said in the release.

Per the agreement terms, Premier will pay the Cloud Practice shareholders up to $5 million in cash in tranches. Initially, it will pay CA$500,000 as refundable deposit when the binding letter of intent (LOI) is signed. Another CA$500,000 will be due on closing of the transaction, with a third CA$500,000 due 90 days after. Within six months of the LOI signing and once certain integration milestones are met, it will pay another CA$500,000. Lastly, Premier will pay an aggregate of CA$3 million in common Premier shares at $0.76 apiece.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Premier Health Group Inc. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Premier Health Group Inc., a company mentioned in this article.

( Companies Mentioned: PHGI:CSE; PHGRF:OTCQB; 6PH:FSE,
)